Validating clinical practice guidelines for the management of children with non-blanching rashes in the UK (PiC): a prospective, multicentre cohort study.


Journal

The Lancet. Infectious diseases
ISSN: 1474-4457
Titre abrégé: Lancet Infect Dis
Pays: United States
ID NLM: 101130150

Informations de publication

Date de publication:
04 2021
Historique:
received: 24 02 2020
revised: 20 04 2020
accepted: 22 05 2020
pubmed: 14 11 2020
medline: 15 4 2021
entrez: 13 11 2020
Statut: ppublish

Résumé

No previous studies have validated current clinical practice guidelines for the management of non-blanching rashes in children who have received meningococcal B and C vaccinations. The aim of this study was to evaluate the performance of existing clinical practice guidelines in the diagnosis of invasive meningococcal disease in children presenting with a fever and non-blanching rash in the UK. The Petechiae in Children (PiC) study was a prospective, multicentre cohort study involving children (aged <18 years) presenting to 37 paediatric emergency departments in the UK with a fever (≥38°C) and a new-onset non-blanching rash or features suggestive of meningococcal infection. Children with pre-existing haematological conditions (ie, haematological malignancy, idiopathic thrombocytopenic purpura, or coagulopathy) or an existing diagnosis of Henoch-Schonlein purpura were excluded. Invasive meningococcal disease was confirmed by positive culture or a quantitative PCR test for Neisseria meningitidis from either blood or cerebrospinal fluid samples. The primary outcome was the performance of six tailored clinical practice guidelines from participating centres (London, Nottingham, Newcastle-Birmingham-Liverpool, Glasgow, Chester, and Bristol) and two clinical practice guidelines from the National Institutes for Health and Care Excellence (NICE; CG102 and NG51) in identifying children with invasive meningococcal disease, assessed by the sensitivity and specificity of each clinical practice guideline. This study is registered with ClinicalTrials.gov, NCT03378258. Between Nov 9, 2017, and June 30, 2019, 1513 patients were screened, of whom 1329 were eligible and were included in the analysis. The median age of patients was 24 months (IQR 12-48). 1137 (86%) of 1329 patients had a blood test and 596 (45%) received parenteral antibiotics. 19 (1%) patients had confirmed meningococcal disease. All eight clinical practice guidelines had a sensitivity of 1·00 (95% CI 0·82-1·00) for identifying meningococcal disease. The specificities of NICE guidelines CG102 (0·01 [95% CI 0·01-0·02]) and NG51 (0·00 [0·00-0·00]) for identifying meningococcal disease were significantly lower than that of tailored clinical practice guidelines (p<0·0001). The best performing clinical practice guidelines for identifying meningococcal disease were the London (specificity 0·36 [0·34-0·39]) and Nottingham (0·34 [0·32-0·37]) clinical practice guidelines. Invasive meningococcal disease is a rare cause of non-blanching rashes in children presenting to the emergency department in the UK. Current NICE guidelines perform poorly when compared with tailored clinical practice guidelines. These findings suggest that UK national guidance could be improved by shifting towards a tailored approach. Public Health Agency.

Sections du résumé

BACKGROUND
No previous studies have validated current clinical practice guidelines for the management of non-blanching rashes in children who have received meningococcal B and C vaccinations. The aim of this study was to evaluate the performance of existing clinical practice guidelines in the diagnosis of invasive meningococcal disease in children presenting with a fever and non-blanching rash in the UK.
METHODS
The Petechiae in Children (PiC) study was a prospective, multicentre cohort study involving children (aged <18 years) presenting to 37 paediatric emergency departments in the UK with a fever (≥38°C) and a new-onset non-blanching rash or features suggestive of meningococcal infection. Children with pre-existing haematological conditions (ie, haematological malignancy, idiopathic thrombocytopenic purpura, or coagulopathy) or an existing diagnosis of Henoch-Schonlein purpura were excluded. Invasive meningococcal disease was confirmed by positive culture or a quantitative PCR test for Neisseria meningitidis from either blood or cerebrospinal fluid samples. The primary outcome was the performance of six tailored clinical practice guidelines from participating centres (London, Nottingham, Newcastle-Birmingham-Liverpool, Glasgow, Chester, and Bristol) and two clinical practice guidelines from the National Institutes for Health and Care Excellence (NICE; CG102 and NG51) in identifying children with invasive meningococcal disease, assessed by the sensitivity and specificity of each clinical practice guideline. This study is registered with ClinicalTrials.gov, NCT03378258.
FINDINGS
Between Nov 9, 2017, and June 30, 2019, 1513 patients were screened, of whom 1329 were eligible and were included in the analysis. The median age of patients was 24 months (IQR 12-48). 1137 (86%) of 1329 patients had a blood test and 596 (45%) received parenteral antibiotics. 19 (1%) patients had confirmed meningococcal disease. All eight clinical practice guidelines had a sensitivity of 1·00 (95% CI 0·82-1·00) for identifying meningococcal disease. The specificities of NICE guidelines CG102 (0·01 [95% CI 0·01-0·02]) and NG51 (0·00 [0·00-0·00]) for identifying meningococcal disease were significantly lower than that of tailored clinical practice guidelines (p<0·0001). The best performing clinical practice guidelines for identifying meningococcal disease were the London (specificity 0·36 [0·34-0·39]) and Nottingham (0·34 [0·32-0·37]) clinical practice guidelines.
INTERPRETATION
Invasive meningococcal disease is a rare cause of non-blanching rashes in children presenting to the emergency department in the UK. Current NICE guidelines perform poorly when compared with tailored clinical practice guidelines. These findings suggest that UK national guidance could be improved by shifting towards a tailored approach.
FUNDING
Public Health Agency.

Identifiants

pubmed: 33186517
pii: S1473-3099(20)30474-6
doi: 10.1016/S1473-3099(20)30474-6
pii:
doi:

Substances chimiques

DNA, Bacterial 0
Meningococcal Vaccines 0

Banques de données

ClinicalTrials.gov
['NCT03378258']

Types de publication

Comparative Study Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

569-577

Investigateurs

Amy Kitching (A)
Matthew Rotheram (M)
Gisela Robinson (G)
Paula Brassey (P)
Stuart Hartshorn (S)
Rachel Wane (R)
Mark Lyttle (M)
Jo Dangerfield (J)
Michael Hayes (M)
Rebecca McFarlane (R)
Helen Armstrong (H)
Damian Roland (D)
Sally Smith (S)
Carl VanHeyningen (C)
Sally Smith (S)
Esther Wilson (E)
Lisa Kehler (L)
Christopher Gough (C)
Fraser Scott (F)
Claire Backhouse (C)
Sylvester Gomes (S)
Darryl Wood (D)
Julie-Ann Maney (JA)
Graham Johnson (G)
Steven Foster (S)
Ben Bloom (B)
Andrew Lancaster (A)
Sebastian Gray (S)
Shammi Ramlakhan (S)
Sharryn Gardner (S)
Sharon Floyd (S)
Chris Cleaver (C)
Susan MacFarlane (S)
Claire Bell (C)
Maggie Nyirenda (M)
Jane Bayreuther (J)
Asim Ijaz (A)
Natalie Rogers (N)
Sarah Wilson (S)
Sarah Diment (S)
Caroline Boulind (C)
Kathryn Allison (K)
Thomas Waterfield (T)
Derek Fairley (D)
James McKenna (J)
Michael Corr (M)
Lisa McFetridge (L)
Hannah Mitchell (H)
Kerry Woolfall (K)
Fiona Lynn (F)
Bethany Petenall (B)
Michael Shields (M)

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

Thomas Waterfield (T)

Emergency Department, Children's Health Ireland at Temple Street, Dublin, Ireland; Centre for Experimental Medicine, Wellcome Wolfson Institute of Experimental Medicine, Belfast, UK. Electronic address: t.waterfield@qub.ac.uk.

Juli-Ann Maney (JA)

Emergency Department, Royal Belfast Hospital for Sick Children, Belfast, UK.

Derek Fairley (D)

Centre for Experimental Medicine, Wellcome Wolfson Institute of Experimental Medicine, Belfast, UK; Department of Microbiology, Belfast Health and Social Care Trust, Belfast, UK.

Mark D Lyttle (MD)

Emergency Department, Bristol Royal Hospital for Children, Bristol, UK; Faculty of Health and Applied Sciences, University of the West of England, Bristol, UK.

James P McKenna (JP)

Department of Microbiology, Belfast Health and Social Care Trust, Belfast, UK.

Damian Roland (D)

SAPPHIRE Group, Health Sciences, Leicester University, Leicester, UK; Children's Emergency Department, Leicester Royal Infirmary, Leicester, UK.

Michael Corr (M)

Emergency Department, Belfast Health and Social Care Trust, Belfast, UK.

Lisa McFetridge (L)

Mathematical Sciences Research Centre, Queen's University Belfast, Belfast, UK.

Hannah Mitchell (H)

Mathematical Sciences Research Centre, Queen's University Belfast, Belfast, UK.

Kerry Woolfall (K)

Institute of Population Health and Society, University of Liverpool, Liverpool, UK.

Fiona Lynn (F)

School of Nursing and Midwifery, Centre for Evidence and Social Innovation, Queen's University Belfast, Belfast, UK.

Bethany Patenall (B)

Department of Chemistry, University of Bath, Bath, UK.

Michael D Shields (MD)

Centre for Experimental Medicine, Wellcome Wolfson Institute of Experimental Medicine, Belfast, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH